臨床應(yīng)用現(xiàn)狀
        自2004年4月上市以來，臨床醫(yī)生已用今又生治療數(shù)萬例惡性腫瘤患者，已治療的腫瘤類型包括起源于多種組織來源的惡性腫瘤，包括頭頸部惡性腫瘤、肝癌、肺癌、食管癌、消化道腫瘤、乳腺癌、子宮頸癌、卵巢癌、膀胱癌等。在國內(nèi)外生物學(xué)雜志發(fā)表的文章達(dá)130多篇，其中包括在臨床腫瘤學(xué)最權(quán)威的雜志：Journal of Clinical Oncology。應(yīng)用途徑也由單純瘤內(nèi)注射發(fā)展到動(dòng)脈內(nèi)給藥、胸腹腔灌注和靜脈滴注等。

今又生具眾多優(yōu)點(diǎn)
        總結(jié)臨床應(yīng)用結(jié)果，今又生治療惡性腫瘤有多項(xiàng)優(yōu)點(diǎn)：1）基本生物學(xué)機(jī)制非常明確；2) 多途經(jīng)多方面抗腫瘤作用； 3) 廣譜的抗腫瘤作用； 4) 高度的安全性，提高患者的生活質(zhì)量；5）和其它腫瘤治療方法有很好的協(xié)同作用，基礎(chǔ)研究和臨床應(yīng)用都證明，今又生?可以增強(qiáng)化療、放療和熱療的療效，并用于手術(shù)前（使腫瘤縮小、腫瘤組織結(jié)構(gòu)變化，增加手術(shù)切除機(jī)會(huì)或縮小手術(shù)切除范圍），手術(shù)中（切口邊緣或殘留腫瘤組織內(nèi)注射）或手術(shù)后。

Present Status of Clinical Application 
Since its introduction in market, Gendicine? has been used to treat tens of thousands malignant tumor patients, including tumors of multiple tissue/ cell origin such as liver, lung, esophageal, alimentary canal, breast, cervical, ovarian, head & neck and bladder cancer. The results were published in national and international journals, including the authoritative ‘Journal of Clinical Oncology’. The route of administration has been extended from its original direct

intra-tumoral injection to intra-arterial, thoracic infusion and intravenous dripping methods.

 Advantages of using Gendicine 
To summarize the clinical results, the advantages of Gendicine? in the treatment of cancer are: 1) the biological mechanism is very clear, 2) multiple effect against cancer, 3) wide spectrum anti-tumor type, 4) high safety margin would allow better quality of life for patients, 5) high synergistic effect with other treatment modalities. The basic and clinical sciences studies have confirmed the synergistic effect of Gendicine? in chemo-, radio-, thermotherapy. Pre-surgical use of the drug can shrink the tumor size, structure and area of involvement, and tumor-normal tissue junction injection peri-operatively.